← Oncology Approval Tracker

FDA DECISION ·

Zejula

niraparib · GlaxoSmithKline

FDA approvalIndication revisionOvarian, fallopian tube, and primary peritoneal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Restricts first-line maintenance after complete or partial response to platinum chemotherapy in adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer to homologous recombination deficiency-positive disease, defined by a deleterious or suspected deleterious BRCA mutation or genomic instability.

LAMPGEN ANALYSIS

Why it matters

FDA narrowed the previous first-line maintenance label to an HRD-positive population.

What research teams should watch

Obtain HRD information in time for the maintenance decision and distinguish this first-line restriction from the separate recurrent maintenance label.

PRIMARY RECORDS

Sources